Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
life sciences
national blog main
national top stories
san francisco blog main
4
×
san francisco top stories
biotech
blueprint medicines
cancer
clinical trials
fda
indiana blog main
indiana top stories
roche
avapritinib
boston
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
europe blog main
europe top stories
genentech
medullary thyroid cancer
national
new york blog main
new york top stories
non-small cell lung cancer
pralsetinib
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
selpercatinib
texas blog main
texas top stories
What
cancer
4
×
drug
fda
4
×
approval
blueprint
genetic
marketing
medicine
medicines
ret
address
approved
approves
candidate
carries
certain
currently
deeper
designed
dna
eisai
fingerprint
flags
going
higher
incidence
latest
lorcaserin
loss
market
matter
muscle
nd
new
oks
pact
pass
patients
post
pulls
Language
unset
Current search:
fda
×
cancer
×
" san francisco blog main "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues